<?xml version="1.0" encoding="UTF-8"?>
<p>Viral hepatitis is the seventh leading cause of mortality globally.
 <xref rid="hep41310-bib-0001" ref-type="ref">1</xref> A third of this mortality is attributed to hepatitis C virus (HCV), a major cause of acute viral hepatitis and liver fibrosis, cirrhosis, and cancer.
 <xref rid="hep41310-bib-0001" ref-type="ref">1</xref>, 
 <xref rid="hep41310-bib-0002" ref-type="ref">2</xref>, 
 <xref rid="hep41310-bib-0003" ref-type="ref">3</xref>, 
 <xref rid="hep41310-bib-0004" ref-type="ref">4</xref> In the Middle East and North Africa (MENA), HCV accounts for two thirds of viral hepatitis mortality and disability‐adjusted life years.
 <xref rid="hep41310-bib-0001" ref-type="ref">1</xref>, 
 <xref rid="hep41310-bib-0004" ref-type="ref">4</xref> Although exposure to HCV infection has been estimated at 1%‐3% in most countries,
 <xref rid="hep41310-bib-0002" ref-type="ref">2</xref>, 
 <xref rid="hep41310-bib-0005" ref-type="ref">5</xref> disproportionate infection levels are found in the MENA countries.
 <xref rid="hep41310-bib-0002" ref-type="ref">2</xref>, 
 <xref rid="hep41310-bib-0003" ref-type="ref">3</xref>, 
 <xref rid="hep41310-bib-0005" ref-type="ref">5</xref>, 
 <xref rid="hep41310-bib-0006" ref-type="ref">6</xref> In this region, antibody prevalence has reached high levels in populous countries, particularly in Egypt and Pakistan, at 10.0%
 <xref rid="hep41310-bib-0007" ref-type="ref">7</xref>, 
 <xref rid="hep41310-bib-0008" ref-type="ref">8</xref>, 
 <xref rid="hep41310-bib-0009" ref-type="ref">9</xref>, 
 <xref rid="hep41310-bib-0010" ref-type="ref">10</xref> and 4.8%,
 <xref rid="hep41310-bib-0011" ref-type="ref">11</xref>, 
 <xref rid="hep41310-bib-0012" ref-type="ref">12</xref>, 
 <xref rid="hep41310-bib-0013" ref-type="ref">13</xref> respectively.
</p>
